Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jan 30;2(1):1.
doi: 10.1186/1475-2859-2-1.

The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi

Affiliations

The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi

Vivi Joosten et al. Microb Cell Fact. .

Abstract

In this review we will focus on the current status and views concerning the production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. We will focus on single-chain antibody fragment production (scFv and VHH) by these lower eukaryotes and the possible applications of these proteins. Also the coupling of fragments to relevant enzymes or other components will be discussed. As an example of the fusion protein strategy, the 'magic bullet' approach for industrial applications, will be highlighted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematical representation of the structure of a conventional IgG and fragments that can be generated thereof. The constant heavy-chain domains CH1, CH2 and CH3 are shown in yellow, the constant light-chain domain (CL) in green and the variable heavy-chain (VH) or light-chain (VL) domains in red and orange, respectively. The antigen binding domains of a conventional antibody are Fabs and Fv fragments. Fab fragments can be generated by papain digestion. Fvs are the smallest fragments with an intact antigen-binding domain. They can be generated by enzymatic approaches or expression of the relevant gene fragments (the recombinant version). In the recombinant single-chain Fv fragment, the variable domains are joined by a peptide linker. Both possible configurations of the variable domains are shown, i.e. the carboxyl terminus of VH fused to the N-terminus of VL and vice versa.
Figure 2
Figure 2
Schematical representation of the structure of a conventional IgG, a heavy-chain IgG antibody and the variable heavy-chain antibody fragment (VHH) that can be generated of the latter. Heavy-chain antibodies found in llama and camel are only composed of heavy-chains and lack the light chain completely, as shown in this Figure. The antigen-binding domain consists of only the VH domain, which is referred to as VHH (variable heavy-chain antibody fragment), to distinguish it from a normal VH. The constant heavy-chain domains CH1, CH2 and CH3 are shown in yellow, the constant light-chain domain (CL) in green and the variable heavy-chain (VH or VHH) or light-chain (VL) domains in red and orange, respectively.
Figure 3
Figure 3
Schematical example of the 'Magic bullet' approach in consumer applications, where an antibody fragment (in this case a llama variable heavy-chain antibody fragment; VHH) recognising a spot on textile, is coupled to an effector molecule (in this case A. ramosus peroxidase; ARP). ARP is a peroxidase, which utilises hydrogen peroxide to catalyse the oxidation of a wide range of organic and inorganic compounds, which makes the enzyme suitable for use in bleaching processes [139].

Similar articles

Cited by

References

    1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497. - PubMed
    1. Porter P, Coley J, Gani M. Immunochemical criteria for successful matching of monoclonal antibodies to immunoassays of peptide hormones for assessment of pregnancy and ovulation. Prog Clin Biol Res. 1988;285:181–200. - PubMed
    1. Van der Linden RHJ. Unique characteristics of llama heavy chain antibodies. PhD thesis Utrecht University Utrecht (The Netherlands) 1999.
    1. Frenken LG, Hessing JG, Van den Hondel CA, Verrips CT. Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganisms. Res Immunol. 1998;149:589–599. - PubMed
    1. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol. 1994;12:433–455. - PubMed